Increased total serum IgE levels in patients with asthma and promoter polymorphisms at CTLA4 and FCER1B

Citation
N. Hizawa et al., Increased total serum IgE levels in patients with asthma and promoter polymorphisms at CTLA4 and FCER1B, J ALLERG CL, 108(1), 2001, pp. 74-79
Citations number
37
Categorie Soggetti
Clinical Immunolgy & Infectious Disease",Immunology
Journal title
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
ISSN journal
00916749 → ACNP
Volume
108
Issue
1
Year of publication
2001
Pages
74 - 79
Database
ISI
SICI code
0091-6749(200107)108:1<74:ITSILI>2.0.ZU;2-U
Abstract
Background: Increasing evidence indicates that total serum IgE levels are l argely determined by genetic factors, and we recently established that the -109C/T promoter polymorphism at FCER1B is a genetic factor that affects to tal serum IgE levels. The gene encoding cytotoxic T lymphocyte antigen 4 (C TLA4) is another candidate factor in high IgE responsiveness, because B7-CD 28/CTLA4 interaction can promote the differentiation and development of the T(H)2 lymphocyte subset. Objective: We intended to determine whether CTLA4 is associated with increa sed levels of total serum IgE or with the development of asthma or atopy. Methods: We performed a case-control study involving 339 patients with asth ma and 305 healthy control subjects, of whom 226 of the patients with asthm a and 219 of the healthy control subjects had previously been genotyped for the -109C/T promoter polymorphism at FCER1B. In the current study, we geno typed 2 polymorphisms in the CTLA4 gene, one involving the promoter (-318C/ T) and the other involving exon I ((+)49A/G), in addition to the FCER1B pro moter polymorphism. Results: Patients with asthma who were homozygous for the -318C allele at t he CTLA4 promoter region had higher levels of total serum IgE than patients with asthma carrying the -318T allele (P = .00470). The analysis of -318C/ T (at CTLA4) and -109C/T (at FCER1B) promoter polymorphisms showed a signif icant correlation between the combined genotypes and increased levels of to tal IgE in patients with asthma (P = .000014). In contrast, no correlation between total serum IgE levels and -318C/T or +49A/G genotypes was detected in 305 healthy control subjects. There was no evidence indicating an assoc iation between a putative allele for asthma or atopy and alleles at any of the CTLA4 polymorphic loci. Conclusion: Our findings suggest that promoter polymorphisms of both CTLA4 and FCER1B are genetic factors that influence total serum IgE levels in pat ients with asthma. This supports the theory that variance in total serum Ig E levels in patients with asthma is determined by mutations in multiple gen es, each of which has a relatively small effect on the phenotype.